APP
HRTX icon

Avantax Planning Partners’s Heron Therapeutics HRTX Stock Holding History

Avantax Planning Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-122
Closed -$4K – 684
2018
Q3 		$4K Buy
+122
New +$4.54K ﹤0.01% 1165
2018
Q2 		– Sell
-160
Closed -$4K – 767
2018
Q1 		$4K Buy
+160
New +$3.63K ﹤0.01% 1419

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Avantax Planning Partners's HRTX Position: Q4 2018 in Review

Avantax Planning Partners sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 122 shares — an estimated $4K sold.

Avantax Planning Partners first reported a position in HRTX in Q1 2018 and held it in 2 quarters. The position peaked at $4K in Q3 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

  • Avantax Planning Partners reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 122 Heron Therapeutics shares in Q4 2018, an estimated $4K.
  • Avantax Planning Partners first reported a position in Heron Therapeutics in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Heron Therapeutics position peaked at $4K in Q3 2018.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.